GlassScriptPhysician profile
Lidia S Pomaville
NPI 1144595174
$62,295.17
in general payments reported to CMS, 2019-2025
35 companies · $27K in 2025
The $27K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14K · 2022: $10K · 2023: $3,197 · 2024: $7,923 · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $15K · Consulting Fee: $2,338 · Education: $878 · Travel and Lodging: $378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,920.00 |
| Food and Beverage | $14,929.63 |
| Consulting Fee | $2,338.00 |
| Education | $878.33 |
| Travel and Lodging | $378.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $21,143.06 | 2021-2025 | Nemluvio, Aklief |
| Vyne Pharmaceuticals INC. | $10,961.85 | 2021 | |
| Epi Health, LLC | $5,752.49 | 2021-2022 | |
| Janssen Biotech, INC. | $3,104.07 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $2,590.30 | 2022-2025 | Sotyktu |
| Abbvie INC. | $2,325.33 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $2,128.92 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Incyte Corporation | $1,721.84 | 2022-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $1,411.49 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $1,376.04 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $1,253.33 | 2021-2025 | Bimzelx, Cimzia |
| Journey Medical Corporation | $1,005.21 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $887.90 | 2021-2025 | |
| Leo Pharma INC. | $851.05 | 2021-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $734.90 | 2022-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $670.33 | 2021-2023 | Grafix |
| Pfizer INC. | $650.55 | 2021-2025 | |
| Dermavant Sciences, INC. | $622.67 | 2023-2024 | Vtama |
| Amgen INC. | $618.25 | 2022-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $468.58 | 2022-2025 | Dupixent, Libtayo |
| Mayne Pharma Commercial LLC | $368.12 | 2022-2025 | |
| Organon LLC | $273.31 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $242.60 | 2021-2025 | Jublia, Cabtreo, Siliq |
| Medimetriks Pharmaceuticals, INC. | $219.05 | 2022-2025 | Neo-Synalar, Clindacin Etz |
| Merz North America, INC. | $197.62 | 2021-2024 | |
| Verrica Pharmaceuticals INC. | $182.69 | 2023-2025 | Ycanth |
| Biofrontera INC. | $148.28 | 2021-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.88 | 2024-2025 | Spevigo |
| Blueprint Medicines Corporation | $100.70 | 2025 | Ayvakit |
| Paratek Pharmaceuticals, INC. | $41.29 | 2021-2022 | |
| Almirall LLC | $31.35 | 2022 | |
| Nabriva Therapeutics, Plc | $30.62 | 2022 | |
| Dermira, INC. | $22.04 | 2021 | |
| Organogenesis INC. | $21.00 | 2025 | Puraply Wound Matrix |
| Mission Pharmacal Company | $13.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lidia Pomaville listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.